Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are uninsured and underinsured and whose out-of-pocket costs exceed Brenzavvy's cash ...
Integration of prescription drug dispensing optimization aritifical intelligence platform EinsteinRx into pharmacy client point-of-sales systems has commencedEinsteinRx integration streamlining effort ...
TAMPA, FL / ACCESS Newswire / December 8, 2025 / Wellgistics Health, Inc. (“Wellgistics”) (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback